Sigachi Industries FY25 revenue surges 25%, EBITDA 46%
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
The CDMO upgrade represents a transformational step for Remedium Lifecare
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Subscribe To Our Newsletter & Stay Updated